ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v21i4.2788ppharm-2500Research ArticleКЛИНИЧЕСКИЙ СЛУЧАЙCASE REPORTНовые перспективы применения дупилумаба в достижении контроля над болезнью у пациентов дошкольного возраста с атопическим дерматитом: клинический случайNew Opportunities of Dupilumab in Achieving Disease Control in Preschool Age Patients with Atopic Dermatitis: Clinical Casehttps://orcid.org/0000-0002-2460-7718ЛевинаЮ. Г.LevinaJulia G.

Левина Юлия Григорьевна, д.м.н.

119333, г. Москва, ул. Фотиевой, д. 10, стр. 1

тел.: +7 (499) 400-47-33

Julia G. Levina, MD, PhD

10, Fotievoy Str., building 1, Moscow, 119333

tel.: +7 (499) 400-47-33

julia.levina@mail.ruhttps://orcid.org/0000-0003-1649-5493ПыжьяноваП. А.PyzhyanovaPolina A.

Пыжьянова Полина Александровна 

Москва

Polina A. Pyzhyanova, MD

Moscow

polinapzh@mail.ruhttps://orcid.org/0000-0002-3781-8661КалугинаВ. Г.KaluginaVera G.

Калугина Вера Геннадьевна, к.м.н.

Москва

Vera G. Kalugina, MD, PhD

Moscow

v-starikova@mail.ruhttps://orcid.org/0000-0003-0317-2425ЭфендиеваК. Е.EfendievaKamilla E.

Эфендиева Камилла Евгеньевна, к.м.н. 

Москва

Kamilla E. Efendieva, MD, PhD

Moscow

kamillaef@inbox.ruhttps://orcid.org/0000-0001-7398-0562ВишневаЕ. А.VishnevaElena A.

Вишнева Елена Александровна, д.м.н., профессор

Москва

Elena A. Vishneva, MD, PhD, Professor

Moscow

vishneva.e@yandex.ruhttps://orcid.org/0000-0001-5665-7835АлексееваА. А.AlekseevaAnna A.

Алексеева Анна Александровна, к.м.н.

Москва

Anna A. Alekseeva, MD, PhD

Moscow

aleksaa06@yandex.ruhttps://orcid.org/0000-0002-2209-7531Намазова-БарановаЛ. С.Namazova-BaranovaLeyla S.

Намазова-Баранова Лейла Сеймуровна, д.м.н., профессор, академик РАН

Москва

Leyla S. Namazova-Baranova, MD, PhD, Professor, Academician of the RAS

Moscow

leyla.s.namazova@gmail.comНИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского»; РНИМУ им. Н.И. ПироговаРоссияResearch Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of Surgery; Pirogov Russian National Research Medical UniversityRussian FederationРНИМУ им. Н.И. ПироговаРоссияPirogov Russian National Research Medical UniversityRussian FederationНИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского»РоссияResearch Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of SurgeryRussian Federation202416092024214361368Copyright © Левина Ю.Г., Пыжьянова П.А., Калугина В.Г., Эфендиева К.Е., Вишнева Е.А., Алексеева А.А., Намазова-Баранова Л.С., 20242024Левина Ю.Г., Пыжьянова П.А., Калугина В.Г., Эфендиева К.Е., Вишнева Е.А., Алексеева А.А., Намазова-Баранова Л.С.Levina J.G., Pyzhyanova P.A., Kalugina V.G., Efendieva K.E., Vishneva E.A., Alekseeva A.A., Namazova-Baranova L.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/2500

Обоснование. Атопический дерматит (АтД) является одним из наиболее распространенных хронических воспалительных заболеваний кожи у детей и в большинстве случаев дебютирует в первый год жизни. Ранняя манифестация АтД — фактор риска развития других заболеваний атопического спектра в дальнейшем. На данный момент широко обсуждается способность генно-инженерного биологического препарата (ГИБП) дупилумаб модифицировать течение болезни, снижать вероятность персистирования АтД и формирования мультиморбидного атопического фенотипа. В связи с этим особый интерес вызывает возможность применения дупилумаба у детей младшего возраста с ранним дебютом и тяжелым течением заболевания. Описание клинического случая. В статье продемонстрирован опыт эффективного применения ГИБП дупилумаб у пациента 4 лет с тяжелой формой АтД и сопутствующей пищевой аллергией. На фоне непрерывной терапии в течение 12 нед удалось купировать кожные проявления болезни. Нежелательных явлений при применении препарата не отмечено. Заключение. Длительное непрерывное использование дупилумаба у детей в возрасте от 6 мес до 5 лет доказало свою эффективность и приемлемый профиль безопасности. Потенциальный болезнь-модифицирующий эффект дупилумаба особенно значим для детей раннего и дошкольного возраста в связи с высоким риском развития именно в этот период атопической мультиморбидности.

Background. Atopic dermatitis (AD) is one of the most common chronic inflammatory skin diseases in children. It manifests during the first year of life in majority of cases. Early AD manifestation is a risk factor for the development of other atopic spectrum diseases in the future. Nowadays, the ability of the dupilumab, as a genetically engineered biologic drug (GEBD), to modify the disease course, to reduce the frequency of AD persistence and the possibility of multimorbid atopic phenotype development is widely discussed. Thus, dupilumab management in young children with early onset and severe course arouses specific interest. Clinical case description. This article demonstrates the experience of effective administration of GEBD dupilumab in 4-year old patient with severe AD and comorbid food allergies. Continuous therapy for 12 weeks allowed to recover disease’s skin manifestations. No adverse events were reported. Conclusion. Long-term continuous dupilumab administration in children aged from 6 months to 5 years has proven its efficacy and acceptable safety profile. The potential disease-modifying effect of dupilumab is especially significant for young and preschool children due to the high risk atopic multimorbidity developing during this period.

детиатопический дерматитатопический маршлечениедупилумабклинический случайchildrenatopic dermatitisatopic marchmanagementdupilumabclinical caseОтсутствует.Not specified.ReferencesАтопический дерматит у детей: клинические рекомендации / Союз педиатров России; Российская ассоциация аллергологов и клинических иммунологов; Российское общество дерматовенерологов и косметологов. — М.; 2021. — 81 с. Доступно по: https://cr.minzdrav.gov.ru/schema/265_2. Ссылка активна на 22.07.2024.Atopicheskii dermatit u detei: Clinical guidelines. Union of Pediatricians of Russia; Russian Association of Allergists and Clinical Immunologists; Russian Society of Dermatovenerologists and Cosmetologists. Moscow; 2021. 81 p. (In Russ). Доступно по: https://cr.minzdrav.gov.ru/schema/265_2. Ссылка активна на 22.07.2024.Bylund S, Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Derm Venereol. 2020;100(12):adv00160. doi: https://doi.org/10.2340/00015555-3510Bylund S, Kobyletzki LB, Svalstedt M, Svensson Å. Prevalence and Incidence of Atopic Dermatitis: A Systematic Review. Acta Derm Venereol. 2020;100(12):adv00160. doi: https://doi.org/10.2340/00015555-3510Амбарчян Э.Т., Намазова-Баранова Л.С., Кузьминова А.Д. и др. Дискуссионные вопросы иммунопатогенеза псориаза и атопического дерматита // Вестник Российской академии медицинских наук. — 2023. — Т. 78. — № 6. — C. 582–588. — doi: https://doi.org/10.15690/vramn9965Ambarchian ET, Namazova-Baranova LS, Kuzminova AD, et al. Controversial Issues of Immunopathogenesis of Psoriasis and Atopic Dermatitis. Annals of the Russian academy of medical sciences. 2023;78(6):582–588. doi: https://doi.org/10.15690/vramn9965Çetinarslan T, Kümper L, Fölster-Holst R. The immunological and structural epidermal barrier dysfunction and skin microbiome in atopic dermatitis-an update. Front Mol Biosci. 2023;10:1159404. doi: https://doi.org/10.3389/fmolb.2023.1159404Çetinarslan T, Kümper L, Fölster-Holst R. The immunological and structural epidermal barrier dysfunction and skin microbiome in atopic dermatitis-an update. Front Mol Biosci. 2023;10:1159404. doi: https://doi.org/10.3389/fmolb.2023.1159404Yang L, Fu J, Zhou Y. Research Progress in Atopic March. Front Immunol. 2020;11:1907. doi: https://doi.org/10.3389/fimmu.2020.01907Yang L, Fu J, Zhou Y. Research Progress in Atopic March. Front Immunol. 2020;11:1907. doi: https://doi.org/10.3389/fimmu.2020.01907Paller AS, Spergel JM, Mina-Osorio P, Irvine AD. The atopic march and atopic multimorbidity: many trajectories, many pathways. J Allergy Clin Immunol. 2019;143(1):46–55. doi: https://doi.org/10.1016/j.jaci.2018.11.006Paller AS, Spergel JM, Mina-Osorio P, Irvine AD. The atopic march and atopic multimorbidity: many trajectories, many pathways. J Allergy Clin Immunol. 2019;143(1):46–55. doi: https://doi.org/10.1016/j.jaci.2018.11.006Furue M, Ulzii D, Vu YH, et al. Pathogenesis of Atopic Dermatitis: Current Paradigm. Iran J Immunol. 2019;16(2):97–107. doi: https://doi.org/10.22034/IJI.2019.80253Furue M, Ulzii D, Vu YH, et al. Pathogenesis of Atopic Dermatitis: Current Paradigm. Iran J Immunol. 2019;16(2):97–107. doi: https://doi.org/10.22034/IJI.2019.80253Hönzke S, Wallmeyer L, Ostrowski A, et al. Influence of Th2 Cytokines on the Cornified Envelope, Tight Junction Proteins, and ß-Defensins in Filaggrin-Deficient Skin Equivalents. J Invest Dermatol. 2016;136(3):631–639. doi: https://doi.org/10.1016/j.jid.2015.11.007Hönzke S, Wallmeyer L, Ostrowski A, et al. Influence of Th2 Cytokines on the Cornified Envelope, Tight Junction Proteins, and ß-Defensins in Filaggrin-Deficient Skin Equivalents. J Invest Dermatol. 2016;136(3):631–639. doi: https://doi.org/10.1016/j. jid.2015.11.007Huang IH, Chung WH, Wu PC, Chen CB. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review. Front Immunol. 2022;13:1068260. doi: https://doi.org/10.3389/fimmu.2022Huang IH, Chung WH, Wu PC, Chen CB. JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review. Front Immunol. 2022;13:1068260. doi: https://doi.org/10.3389/fimmu.2022Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol. 2021;17(8):835–852. doi: https://doi.org/10.1080/1744666X.2021.1940962Dubin C, Del Duca E, Guttman-Yassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol. 2021;17(8):835–852. doi: https://doi.org/10.1080/1744666X.2021.1940962Stefanovic N, Irvine AD. Filaggrin and beyond: New insights into the skin barrier in atopic dermatitis and allergic diseases, from genetics to therapeutic perspectives. Ann Allergy Asthma Immunol. 2024;132(2): 187–195. doi: https://doi.org/10.1016/j.anai.2023.09.009Stefanovic N, Irvine AD. Filaggrin and beyond: New insights into the skin barrier in atopic dermatitis and allergic diseases, from genetics to therapeutic perspectives. Ann Allergy Asthma Immunol. 2024;132(2): 187–195. doi: https://doi.org/10.1016/j.anai.2023.09.009Schmitt J, Spuls PI, Thomas KS, et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134(4): 800–807. doi: https://doi.org/10.1016/j.jaci.2014.07.043Schmitt J, Spuls PI, Thomas KS, et al. The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol. 2014;134(4): 800–807. doi: https://doi.org/10.1016/j.jaci.2014.07.043Lewis-Jones MS, Finlay AY, Dykes PJ. The Infants’ Dermatitis Quality of Life Index. Br J Dermatol. 2001;144(1):104–110. doi: https://doi.org/10.1046/j.1365-2133.2001.03960.xLewis-Jones MS, Finlay AY, Dykes PJ. The Infants’ Dermatitis Quality of Life Index. Br J Dermatol. 2001;144(1):104–110. doi: https://doi.org/10.1046/j.1365-2133.2001.03960.xWollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema — part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904–1926. doi: https://doi.org/10.1111/jdv.18429Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema — part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904–1926. doi: https://doi.org/10.1111/jdv.18429Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I — systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. doi: https://doi.org/10.1111/jdv.18345Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I — systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. doi: https://doi.org/10.1111/jdv.18345Olbrich H, Sadik CD, Ludwig RJ, et al. Dupilumab in Inflammatory Skin Diseases: A Systematic Review. Biomolecules. 2023;13(4):634. doi: https://doi.org/10.3390/biom13040634Olbrich H, Sadik CD, Ludwig RJ, et al. Dupilumab in Inflammatory Skin Diseases: A Systematic Review. Biomolecules. 2023;13(4):634. doi: https://doi.org/10.3390/biom13040634Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet. 2022;400(10356):908–919. doi: https://doi.org/10.1016/S0140-6736(22)01539-2Paller AS, Simpson EL, Siegfried EC, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet. 2022;400(10356):908–919. doi: https://doi.org/10.1016/S0140-6736(22)01539-2Lin TL, Fan YH, Fan KS, et al. Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: A population-based cohort study. J Am Acad Dermatol. 2024:S0190- 9622(24)00788-6. doi: https://doi.org/10.1016/j.jaad.2024.05.029Lin TL, Fan YH, Fan KS, et al. Reduced atopic march risk in pediatric atopic dermatitis patients prescribed dupilumab versus conventional immunomodulatory therapy: A population-based cohort study. J Am Acad Dermatol. 2024:S0190- 9622(24)00788-6. doi: https://doi.org/10.1016/j. jaad.2024.05.029Agache I, Akdis CA, Akdis M, et al. EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy. 2021;76(4):988–1009. doi: https://doi.org/10.1111/all.14690Agache I, Akdis CA, Akdis M, et al. EAACI Biologicals Guidelines-dupilumab for children and adults with moderate-to-severe atopic dermatitis. Allergy. 2021;76(4):988–1009. doi: https://doi.org/10.1111/all.14690Paternoster L, Savenije OEM, Heron J, et al. Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts. J Allergy Clin Immunol. 2018;141(3):964–971. doi: https://doi.org/10.1016/j.jaci.2017.09.044Paternoster L, Savenije OEM, Heron J, et al. Identification of atopic dermatitis subgroups in children from 2 longitudinal birth cohorts. J Allergy Clin Immunol. 2018;141(3):964–971. doi: https://doi.org/10.1016/j.jaci.2017.09.044Tran MM, Lefebvre DL, Dharma C, et al. Predicting the atopic march: Results from the Canadian Healthy Infant Longitudinal Development Study. J Allergy Clin Immunol. 2018;141(2):601–607. e8. doi: https://doi.org/10.1016/j.jaci.2017.08.024Tran MM, Lefebvre DL, Dharma C, et al. Predicting the atopic march: Results from the Canadian Healthy Infant Longitudinal Development Study. J Allergy Clin Immunol. 2018;141(2):601–607. e8. doi: https://doi.org/10.1016/j.jaci.2017.08.024Lack G. Epidemiologic risks for food allergy. J Allergy Clin Immunol. 2008;121(6):1331–1336. doi: https://doi.org/10.1016/j.jaci.2008.04.032. PMID: 18539191Lack G. Epidemiologic risks for food allergy. J Allergy Clin Immunol. 2008;121(6):1331–1336. doi: https://doi.org/10.1016/j.jaci.2008.04.032. PMID: 18539191Strid J, Hourihane J, Kimber I, et al. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. Eur J Immunol. 2004;34(8):2100–2109. doi: https://doi.org/10.1002/eji.200425196Strid J, Hourihane J, Kimber I, et al. Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response. Eur J Immunol. 2004;34(8):2100–2109. doi: https://doi.org/10.1002/eji.200425196Gandhi NA, Bennett BL, Graham NM, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50. doi: https://doi.org/10.1038/nrd4624Gandhi NA, Bennett BL, Graham NM, et al. Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov. 2016;15(1):35–50. doi: https://doi.org/10.1038/nrd4624Bieber T. In search of the Holy Grail in atopic dermatitis: Will dupilumab become the first disease-modifying atopic dermatitis drug? J Allergy Clin Immunol. 2023;151(3):694–696. doi: https://doi.org/10.1016/j.jaci.2022.12.824Bieber T. In search of the Holy Grail in atopic dermatitis: Will dupilumab become the first disease-modifying atopic dermatitis drug? J Allergy Clin Immunol. 2023;151(3):694–696. doi: https://doi.org/10.1016/j.jaci.2022.12.824Geba GP, Li D, Xu M, et al. Attenuating the atopic march: Metaanalysis of the dupilumab atopic dermatitis database for incident allergic events. J Allergy Clin Immunol. 2023;151(3):756–766. doi: https://doi.org/10.1016/j.jaci.2022.08.026Geba GP, Li D, Xu M, et al. Attenuating the atopic march: Metaanalysis of the dupilumab atopic dermatitis database for incident allergic events. J Allergy Clin Immunol. 2023;151(3):756–766. doi: https://doi.org/10.1016/j.jaci.2022.08.026Paller AS, Siegfried EC, Simpson EL, et al. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study. Am J Clin Dermatol. 2024;25(4):655–668. doi: https://doi.org/10.1007/s40257-024-00859-yPaller AS, Siegfried EC, Simpson EL, et al. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study. Am J Clin Dermatol. 2024;25(4):655–668. doi: https://doi. org/10.1007/s40257-024-00859-yPaller AS, Siegfried EC, Cork MJ, et al. Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatr Drugs. 2023;25(1):67–77. doi: https://doi.org/10.1007/s40272-022-00553-8Paller AS, Siegfried EC, Cork MJ, et al. Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis. Paediatr Drugs. 2023;25(1):67–77. doi: https://doi.org/10.1007/ s40272-022-00553-8Paller AS, Siegfried EC, Cork MJ, et al. Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis. Paediatr Drugs. 2024;26(2):163–173. doi: https://doi.org/10.1007/s40272-023-00611-9Paller AS, Siegfried EC, Cork MJ, et al. Infections in Children Aged 6 Months to 5 Years Treated with Dupilumab in a Placebo-Controlled Clinical Trial of Moderate-to-Severe Atopic Dermatitis. Paediatr Drugs. 2024;26(2):163–173. doi: https://doi.org/10.1007/s40272-023-00611-9Berna-Rico E, Fiz-Benito E, Busto-Leis JM, et al. Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study. Dermatology. 2024;240(2):337–342. doi: https://doi.org/10.1159/000535282Berna-Rico E, Fiz-Benito E, Busto-Leis JM, et al. Effectiveness and Safety of Dupilumab in Children Under 6 Years of Age with Moderate-to-Severe Atopic Dermatitis: A Retrospective Real-World Study. Dermatology. 2024;240(2):337–342. doi: https://doi.org/10.1159/000535282

The authors declare that there are no conflicts of interest present.